Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just dandy, despite another blanket of snow descending on the Pharmalot campus. A picturesque winter scene can be relaxing, yes? But there is some shoveling in our future. So we are fortifying ourselves with another cup of stimulation — our choice this morning is mountain blueberry — as we also prepare for a panel we will moderate at 1 p.m. ET today on antibiotic resistance. Meanwhile, here are a few items of interest we have gathered. Hope your day goes well and you stay safe. …

A laboratory test suggests the Covid-19 vaccine made by Pfizer (PFE) and BioNTech (BNTX) loses some potency against the coronavirus variant that first appeared in South Africa, STAT writes. What the findings mean for how well the vaccine will protect real people from the variant, called B.1.351, is hard to tell. But clinical data for vaccines made by AstraZeneca (AZN), Novavax (NVAX), and Johnson & Johnson (JNJ) have already shown they are not as powerful at blocking symptomatic Covid-19 cases caused by B.1.351 as by other forms of the virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.